| Original language | English (US) |
|---|---|
| Pages (from-to) | 396-397 |
| Number of pages | 2 |
| Journal | Annals of the American Thoracic Society |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2019 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of the American Thoracic Society, Vol. 16, No. 3, 03.2019, p. 396-397.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Ethics of health research supported by for-profit cannabis companies
T2 - What have we learned from big tobacco?
AU - Burnham, Ellen L.
AU - Eakin, Michelle N.
AU - Pakhale, Smita
N1 - Funding Information: Ethics of Health Research Supported by For-Profit Cannabis Companies: What Have We Learned from Big Tobacco? Funding Information: As clinician-investigators with an interest in the impact of legalized cannabis on pulmonary diseases, we read the results of a clinical trial of vaporized cannabis for advanced chronic obstructive pulmonary disease with enthusiasm (1). We commend the researchers for conducting a well-designed study focused on use of noncombusted cannabis for pulmonary conditions. However, publication of this study by AnnalsATS raises an important point. Together with acknowledging support of the study’s authors by numerous funding sources, including the Canadian Institutes of Health Research, the senior author also received an investigator-initiated study grant from Tilray. Per the company’s website, (www.tilray.com), “Tilray is a global leader in medical cannabis research, cultivation, processing and distribution [that aspires] to lead, legitimize and define the future of our industry by building the world’s most trusted cannabis company.. [W]e are the first GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers..” Tilray was listed on the Nasdaq Stock Market (NASDAQ:TLRY) in July 2018 with a market value reportedly worth $5 billion (2), making it relatively smaller than Philip Morris International or Coca-Cola, each valued at over $100 billion. However, Tilray’s involvement in the study begs the question: Is it ethical to accept a study for publication that has been supported by for-profit cannabis corporations whose products have an unknown and potentially negative impact on human health?
PY - 2019/3
Y1 - 2019/3
UR - http://www.scopus.com/inward/record.url?scp=85062207266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062207266&partnerID=8YFLogxK
U2 - 10.1513/AnnalsATS.201811-764LE
DO - 10.1513/AnnalsATS.201811-764LE
M3 - Letter
C2 - 30712358
AN - SCOPUS:85062207266
SN - 2325-6621
VL - 16
SP - 396
EP - 397
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
IS - 3
ER -